CARE Steering Committee and Dissemination Board

1. CARE Steering Committee and Dissemination Board R. Aleksan (aleksan@dapnia.cea.fr) CARE Steering Committee Paris, April 11, 2006 + • Introduction et objectives • CARE funding andgeneral administrative matters • FP7, ESGARD matters and CARE2

2. Main objectives of the meeting • Review financial situation • Status of EU funding • Total costs • Budget for next 18 months • Review progress in NA/JRA • Discuss the future • FP7 • CARE2

3. Total costs for the 24 first months (2004+2005) Total (5 years) expected costs: 35 141 200 € Total costs for past 24 months: 14 011 451 € (~40%)

4. Total costs for the 24 first months (2004+2005)

5. Total expected cost in 2005: 10 659 423 €

6. Summary of the financial situation

7. Budget for the next 18 months Total expected costs for next 18 months: 12 839 414 € Total costs requested to the EC: 5 644 485 € (we should receive ~2 500 000 €)

8. Annual Report (see O. Napoly)

9. Timetable for FP7 adoption • 6 April 2005 FP7 proposal • 21 September 2005 Specific Prog. proposals • June 2006 ? Adoption • November 2006 ? First calls for proposals • January 2007 ? Launch Conference likely to be delayed by 6 months or so Probably early spring 2007, with the first call being on new infrastructures Delayed accordingly

10. What will ESGARD do next ECFA statement at its meeting in November 2005 R-ECFA acknowledged the successful achievements carried out by ESGARD and encourage the committee to continue structuring the European accelerator R&D, (i.e. defining the strategy, examining the proposals, making recommendations and promoting the projects, in particular with respect to the forthcoming seventh Framework Programme (FP7)). Accordingly, R-ECFA recommended maintaining the initial objectives as written in the mandate of ESGARD: Promoting mutual coordination and facilitating the pooling of European resources. Promoting a coherent and coordinated utilization and development of infrastructures. Promoting inter-disciplinary collaboration including industry. Furthermore, R-ECFA encouraged ESGARD to examine whether any modifications and extensions of its mandate and membership were appropriate and/or necessary in order to enhance further the European activities on accelerator R&D.

11. Met on February 27th to discuss its next actions With the objectives • to continue promoting Accelerator R&D programs in Europe, • to help developing strong and challenging collaborative efforts leading to • outstanding proposals • to develop a strategy, evaluate proposal, set priorities and make recommendation to the appropriate bodies

12. ESGARD actions Call for Letters of Intent for accelerator R&D project With a deadline on April 28th . So as to have a first scope of the ideas of the community by the Zeuthen meeting • “We would like at this point to explore how our community could propose a • coherent set of projects in an organized manner. • To this end, we would like to make a call for Letters of Intent for R&D projects. • These proposals could be • Joint Research Activities (JRA), to be included in I3 proposals, such as the ones in CARE • Design Study (DS) projects, such EUROTeV or EURISOL • Construction of New R&D Infrastructures (CNI-RD), such as a test facility. It should be noted that ESGARD is only concerned by the new infrastructure for carrying accelerator R&D and not the accelerators project for carrying physics programmes.”

13. So far received 6 contributions • CNI: European SC RF facility • DS: DS for neutrino facility • I3-JRA: R&D on SC magnets • I3-JRA: Different SC activities (technology, instrumentation, new RF guns, new SC material) • I3-JRA:Deposition of thin superconducting layers for accelerator technology • I3-JRA:Deposition of superconducting films of pure lead (Pb) by means of the • UHV cathodic arc Next ESGARD meeting at CERN on May 19, 2006

14. ESGARD actions (cont’d) Letter to the Strategy Group stressing the need of accelerator R&D • ESGARD stresses the importance of continuing and enhancing further the European effort both for generic and targeted accelerator R&D. • ESGARD reaffirms the dramatic need for accelerator R&D with the appropriate level of funding coming from the national funding agencies and the EC. Indeed a vigorous R&D effort is vital in order to be ready to launch the construction of new infrastructures in a timely fashion, allowing the community to capitalize on prior European investments and maintain its leadership. • More specifically, this required effort includes R&D toward the upgrades of the LHC and • the CERN accelerator complex, ILC, CLIC, intense neutrino beams, flavor factories and test • accelerator facilities using novel technologies. • Furthermore ESGARD is concerned about the persistent lack of accelerator physicists and stresses the need for enhancing the education, the training and the recruitment of young accelerator physicists. • It is felt also that the appointment of professors in the field of accelerator physics should be • strongly encouraged in the universities and supported by the research institutes. • Finally ESGARD stresses the importance of communicating the outcome of the SG to the • European strategy Forum for Research Infrastructure in a timely manner.

15. ESGARD organization ESGARD propositions to modify its rules The term of the ESGARD members should be limited to 4 years. The members, nominated by the directors of the Particle Physics laboratory in Europe, should be representatives from the major laboratories, i.e. CERN, DESY, CCLRC, CEA (DAPNIA), IN2P3 (Orsay), INFN or INFN-LNF. The possible participation of a representative from a Russian laboratory was raised and will be discussed with the laboratory Directors. As a first step toward involving other communities active in accelerator R&D (e.g. nuclear physics, light sources…), observers from these communities, should be invited to attend the ESGARD meetings when they are concerned by the subjects on the agenda. The question of to whom ESGARD must actually report needs to be clarified. Two routes can be envisaged for this reporting: CERN Council or ECFA.